presented by
Speaker, MD
Hospital Name
Date
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 1
1
Table of Contents
Program Content and Format...................................................... Page 3
Target Audience/Learning Objectives ......................................... Page 3
CME Statements ......................................................................... Page 4
Disclosures .................................................................................. Page 5
Steering Committee Bios............................................................. Pages 6-7
Speaking Faculty Bio ................................................................... Page 8
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 2
2
Program Content and Format
The Potomac Center for Medical Education welcomes you to “Oncology Exchange: Emerging
Agents in HER2-positive Breast Cancer,” a CME-certified Visiting Professor presentation
designed to give medical professionals the latest news and information on HER2-positive breast
cancer.
Community oncologists treat 80% of the cancer patients in the US each year. Data suggest that
community oncologists need assistance staying up to date with the latest data presented at
national/international meetings and on implementing clinical trial findings into practice. Community
oncologists are constantly challenged to stay current with emerging data from ongoing studies of
novel regimens, updated clinical practice guidelines, and eligibility criteria of currently accruing trials
of novel regimens for the treatment of HER2-positive breast cancer. This educational activity is
designed to update community oncologists on recent advances in the management of HER2positive breast cancer to improve patient outcomes.
Visit www.medscape.org/viewcollection/32391 for more information.
Target Audience
This activity is intended for oncologists and other clinicians in the community setting who are
actively involved in the diagnosis, treatment, and management of patients with HER2-postitive
breast cancer.
Educational Objectives
This program is designed to address the following IOM competencies: provide patient-centered
care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
•
Review the recently updated clinical practice guidelines for HER2-positive breast
cancer
•
Discuss recent data with HER2-targeted agents in the neoadjuvant and adjuvant
settings and choose the optimal treatment for patients with early-stage HER2-positive
breast cancer and patients with abnormal cytogenetics
•
Assess the various treatment strategies for patients with locally advanced or
metastatic HER2-positive breast cancer
•
Identify eligibility criteria and the status of currently accruing clinical trials in HER2positive breast cancer and counsel patients accordingly
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 3
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and
policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship
of Potomac Center for Medical Education and Rockpointe. Potomac Center for Medical Education is
accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
CME Credit
The Potomac Center for Medical Education designates this live activity for a
maximum of 1.0 AMA PRA Category I credit(s)TM. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email contact@potomacme.org
Special Services
Event staff will be glad to assist you with any special needs (e.g. physical, dietary,
etc.).
Fee and Receiving CME/CE Credit
There is no fee for this educational activity. To receive CME/CE credit the participant must:

Participate in this one-hour-long program in its entirety;

Sign in / sign out on the sheet provided by the host coordinator;

Complete and sign the registration and evaluation form;

Return the registration and evaluation form to the host coordinator.
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 4
Disclosure Statement
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the
Standards for Commercial Support, set forth to providers by the Accreditation Council for
Continuing Medical Education (ACCME) and all other professional organizations, as applicable,
stating those activities where continuing education credits are awarded must be balanced,
independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program
sponsored by the Potomac Center for Medical Education are required to disclose any relevant
financial relationships with any commercial interest to PCME as well as to learners. All conflicts are
identified and resolved by PCME in accordance with the Standards for Commercial Support in
advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that
the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner
have with commercial interests:
SPEAKING FACULTY:
Faculty Speaker, MD: Consultant: Pharma Name; Clinical Investigator: Pharma Name
STEERING COMMITTEE:
Debu Tripathy, MD: Consultant: Clovis Oncology; Clinical Investigator: Piramal Pharmaceuticals
Kathy Miller, MD: Speaker/Consultant: Genentech/Roche; Consultant: AstraZeneca, Bristol-Myers Squibb
Non-faculty content contributors and/or reviewers reported the following relevant financial
relationships that they or their spouse/partner have with commercial interests:
Latha Shivakumar, PhD; Bradley Pine; Blair St. Amand; Jay Katz: Nothing to Disclose
Michelle Melisko, MD: Speaker: Agendia, Bristol-Myers Squibb, Genentech/Roche, Novartis; Clinical
Investigator: Amgen, AstraZeneca, Celldex
FDA Disclosure
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses
of some agents mentioned. Please consult the prescribing information for full disclosure of
approved uses.
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 5
Steering Committee
DEBU TRIPATHY, MD
Professor of Medicine
University of Southern California
Co-leader, Women’s Cancer Program
USC/Norris Comprehensive Cancer Center
Los Angeles, CA
Debu Tripathy, MD is Professor of Clinical Medicine and Co-leader of the Women’s Cancer
Program, and holds the Priscilla and Art Ulene Chair in Women’s Cancer at the University of
Southern California and USC/Norris Comprehensive Cancer Center. He received a degree in
chemical engineering from the Massachusetts Institute of Technology and then completed medical
school and an internal medicine residency at Duke University, followed by a hematology/oncology
fellowship at the University of California at San Francisco.
His clinical research focuses on the evaluation and development of novel therapeutics in breast
cancer, specifically, growth factor receptor pathway targeting, as well as biomarkers that predict
sensitivity and resistance. Elucidation of specific mechanisms of resistance and synthetic lethal
combinatorial strategies from the laboratory are being applied for early phase therapeutic
applications. Similarly, human tissue studies from patients receiving conventional and targeted
therapies are being analyzed toward the discovery of novel targets and predictive biomarkers.
Dr. Tripathy is also part of a multi-disciplinary team of breast cancer specialists dedicated to patientcentered state-of-the-art and personalized approaches to care, with an emphasis on clinical trials
that interface with the basic scientific strengths at USC and external collaborators. Dr. Tripathy has
published numerous original laboratory and clinical research articles on breast cancer and serves
on several editorial boards, study sections, and society boards, as well as being Editor-in-Chief of
CURE Magazine. He has previously served as the President of the American Society of Breast
Disease and the Society of Integrative Oncology.
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 6
Steering Committee Cont’d
KATHY MILLER, MD
Associate Professor
Sheila D Ward Scholar
IU Simon Cancer Center
Indianapolis, IN
Kathy Miller, MD’s career focuses on translational clinical research in breast cancer. She became
Co-chair of the Eastern Cooperative Oncology Group Breast Core Committee in 2010. In this role,
she has worked with laboratory scientists and community oncologists to develop trials that combine
clinical and biologic endpoints, but remain feasible in non-academic settings.
Dr. Miller first honed her ability to coordinate multi-center trials as Principal Investigator for E2100,
the first phase III trial to confirm the benefits of antiangiogenic therapy in patients with metastatic
breast cancer. Dr. Miller currently leads E5103, an international phase III trial investigating
antiangiogenic therapy in the adjuvant setting. Preclinical studies suggest that inhibition of
telomerase may reverse resistance to trastuzumab in patients with HER2-positive breast cancer.
Dr. Miller brings these findings to the clinic with the first phase I trial of a telomerase inhibitor and
trastuzumab in trastuzumab-resistant patients.
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 7
Faculty Speaker
FACULTY SPEAKER, MD
Title
Title
Affiliation
City, STATE
Faculty Speaker, MD is include rest of bio.
Second paragraph of bio.
Oncology Exchange: Emerging Agents in HER2-positive Breast Cancer
Page 8